Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
Status:
Withdrawn
Trial end date:
2020-06-01
Target enrollment:
Participant gender:
Summary
A multi-institutional, single arm pilot study of antibiotics and pembrolizumab for the
treatment of surgically resectable pancreatic cancer. The primary purpose of this study is to
determine the change in immune activation in pancreatic tumor tissue following treatment with
antibiotics and pembrolizumab.
Phase:
Phase 4
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health